Game changing scientific innovation
We combine independent expertise in drug development with extensive business and scientific experience to navigate the complex pathway from lab to commercialisation. Our desire to drive scientific innovation is founded on a patient-centric vision, a clear business strategy, comprehensive product protection, and strong development partnerships. Our open information policy keeps our partners informed of our achievements while respecting the need for confidentiality.
A clear business strategy
We work hard to identify and develop drug candidates with the potential to satisfy the unmet need for disease modifying therapies. TikoMed AB is an investment/holding company that develops projects through daughter companies. We identify and develop molecules for clinical trial then exit projects through a partnering deal or trade sale to biopharmas capable of progressing the drug candidates to market.
Company information
TikoMed AB is a privately owned company based in Viken, Sweden. It is governed by the Laws of the Kingdom of Sweden and was formed in accordance with the Swedish Company Act in 2002.
Management
Lars Bruce,
Vice President Neurodegeneration - ILB®
VP and Board Member and founder of TikoMed. Lars is leading the research and development program for ILB®, our drug candidate for neurodegenerative diseases currently in clinical development for Amyotrophic Lateral Sclerosis (ALS).
Florence Lange,
Senior Coordinator - ILB®
Senior Coordinator for ILB project with more than 30 years’ experience as a Management- and Executive assistant and the expertise of working in a growing company from early stage to major international presence. Before joining TikoMed, Florence was involved in building up the organization and the administrative structure of an international start-up project.
Hans Peter Ostler,
CEO
Hans-Peter has studied at the School of Busines, Law, Economics and School of Public Administration at Gothenburg Univeristy. HP has more than 20 years experience from investment banking and is currently on several boards for life science companies.
Sten Kornfält,
Project Leader
Sten holds a pharmacy degree from Uppsala University and is a certified project manager. Sten has extensive experience in research, pharmaceutical development and the pharmaceutical industry and has most recently worked as project manager in different small biotech companies and clinical CROs.
Johan Olsson,
Chief Financial Officer
Johan holds a Master Degree of Business Administration from Lund University and specializes in accounting and auditing. Johan has previously worked at Nyström & Partners Revision AB, BJT Consulting AB and Personal Accounting Sweden AB.
Scientific advisory board - SAB
Merit Cudkowicz,
MD, MSC
Dr. Merit Cudkowicz is the Director of the Sean M. Healey & AMG Center for ALS, Chairof Neurology at Mass General, and the Julieanne Dorn Professor of Neurology at Harvard Medical School. Dr. Cudkowicz’s research and clinical activities are dedicated to the study and treatment of people with Amyotrophic Lateral Sclerosis (ALS). Dr. Cudkowicz is one of the founders and past Co-Chairs of the Northeast ALS Consortium (NEALS), a group of over 145 clinical sites in the United States, Canada, Europe and the Middle East dedicated to performing collaborative clinical trials and research in ALS. She has brought innovations to accelerate the development of treatments for people with ALS rapidly.
Caroline Ingre,
MD
Researcher Caroline Ingre is an Associate Professor and Research Group Leader, ALS, at the Department of Clinical Neuroscience at Karolinska Institutet. She is a specialist in neuromuscular disease and have been working with ALS for more than 10 years.
Caroline has initiated several collaborations between Universities and University Hospitals in Sweden and hosts the national clinical ALS meeting. She also leads an ALS research group at Karolinska Institute with main interests in epidemiology, risk and prognosis of ALS disease, the development of imaging methods, biomarker studies and psychological influence on ALS.
Jeremy Shefner,
MD, PhD
Jeremy Shefner, MD, PhD, is a neurologist in the Gregory W. Fulton ALS & Neuromuscular Disease Center and professor in the Department of Neurology at Barrow Neurological Institute. He is board certified in neurology by the American Board of Psychiatry and Neurology and he specializes in ALS and neuromuscular disorders.
Dr. Shefner’s research focuses on biomarker development and the clinical therapeutics of amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy. He co-founded the Northeast ALS Clinical Trials Consortium (NEALS), the largest and most active consortium in the world dedicated to ALS. He directs the NEALS outcomes and clinical monitoring cores and is the principal investigator for two multicenter clinical trials, as well as a biomarker study measuring ALS disease progression.
Dr. Shefner received his PhD from the University of Illinois in Urbana-Champaign, and his MD from Northwestern University Medical School in Chicago. He completed his residency training at the Harvard Longwood Neurology Training Program in Boston and completed a fellowship in neuromuscular disease at the Brigham and Women’s Hospital in Boston.
Prof Adriano Chiò
Prof Adriano Chiò is a neurologist currently working in Torino, Italy. He is Professor of Neurology and Director of the ALS Center at the University of Torino and the Città della Salute e della Scienza Hospital, Torino, Italy. He is director of the ALS Expert Center in Torino, that aims for optimal diagnostic work-up, care and treatment for patients with ALS and other motor neuron diseases in Piedmont. He leads the Italian ALS Genetic (ITALSGEN) Consortium. Adriano Chiò, whose main areas of research are epidemiology, cognition, neuroimaging, and genetics of ALS, is best known for his research on risk of ALS in soccer players, the phenotypic heterogeneity of ALS and has contributed to the discovering of several ALS genes, including C9ORF72, VCP, MATR3 and KIF5A. He has published over 330 papers in peer-reviewed journals. He was awarded the 2015 Sheila Essay Award, presented by the American Academy of Neurology and ALS Association (USA).
Board of directors
Christian Treschow, Chairman
Experienced in private banking for capital and investment advice. Most recently as an Acquisition Manager in Danske Bank Private Banking in Stockholm. Today he is in to forestry and develops a solar park. He holds a Master Degree in economics at Lund University.
Lars Bruce, Board Member
Inventor with commercial innovations in mechanics, metallurgy, and medicine. Founder of SinterCast, Nasdaq Stockholm.
Adam Bruce, Board Member
More than 20 years of experience of leading innovation and project development in Life Sciences.
Jon Nilsson, Board Member
More than 20 years as a professional investor in Life Science and real estate.